136 related articles for article (PubMed ID: 1613560)
1. Rapid development of dopaminergic supersensitivity in reserpine-treated rats demonstrated with 14C-2-deoxyglucose autoradiography.
Trugman JM; James CL
J Neurosci; 1992 Jul; 12(7):2875-9. PubMed ID: 1613560
[TBL] [Abstract][Full Text] [Related]
2. D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography.
Trugman JM
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Sep; 19(5):795-810. PubMed ID: 8539420
[TBL] [Abstract][Full Text] [Related]
3. Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups.
Moody CA; Spear LP
Psychopharmacology (Berl); 1992; 107(1):39-49. PubMed ID: 1350350
[TBL] [Abstract][Full Text] [Related]
4. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
Hu XT; Wachtel SR; Galloway MP; White FJ
J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
[TBL] [Abstract][Full Text] [Related]
5. Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions.
Trugman JM; Wooten GF
J Neurosci; 1987 Sep; 7(9):2927-35. PubMed ID: 3114439
[TBL] [Abstract][Full Text] [Related]
6. D1 dopamine agonist and antagonist effects on regional cerebral glucose utilization in rats with intact dopaminergic innervation.
Trugman JM; James CL
Brain Res; 1993 Apr; 607(1-2):270-4. PubMed ID: 8481802
[TBL] [Abstract][Full Text] [Related]
7. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
8. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
LaHoste GJ; Yu J; Marshall JF
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
[TBL] [Abstract][Full Text] [Related]
9. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
12. D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography.
Trugman JM; Arnold WS; Touchet N; Wooten GF
J Pharmacol Exp Ther; 1989 Sep; 250(3):1156-60. PubMed ID: 2674418
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
Huang KX; Walters JR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
[TBL] [Abstract][Full Text] [Related]
14. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.
Engber TM; Susel Z; Kuo S; Chase TN
J Neurosci; 1990 Dec; 10(12):3889-95. PubMed ID: 1980132
[TBL] [Abstract][Full Text] [Related]
15. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ
Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644
[TBL] [Abstract][Full Text] [Related]
16. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice.
Rubinstein M; Gershanik O; Stefano FJ
Eur J Pharmacol; 1988 Apr; 148(3):419-26. PubMed ID: 2968273
[TBL] [Abstract][Full Text] [Related]
17. Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist?
Jackson DM; Mohell N; Bengtsson A; Malmberg A
Eur J Pharmacol; 1995 Aug; 282(1-3):137-44. PubMed ID: 7498268
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
19. Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.
Ross SB; Jackson DM; Wallis EM; Edwards SR
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):512-8. PubMed ID: 3261844
[TBL] [Abstract][Full Text] [Related]
20. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
Starr BS; Starr MS; Kilpatrick IC
Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
